Pursuant to the requirements of 42 C.F.R. part 456, subpart K, the District of Columbia has established the Drug Utilization Review Board ("DUR Board") at DHCF.
The DUR Board's mission and mandate is to establish reporting structure, use investigatory powers and employ other regulatory measures to confirm that prescribed drugs are clinically appropriate, medically necessary, cost-effective, and not fraudulently obtained or prescribed.
Consistent with 42 C.F.R. § 438.3(s)(4), each Medicaid managed care organization (MCO), or its designee, shall operate its own DUR program consistent with federal requirements. The MCO program must be as comprehensive as the program operated by DHCF.
The DUR Board shall require a monthly report from the Medicaid Management Information System (MMIS) and each MCO, or its designee, to include information identifying beneficiaries who meet criteria for potential misuse or inappropriate use of prescription drugs, such as:
The DUR Board shall require the institution of safety edits on opioid prescriptions.
The DUR Board shall evaluate and develop guidelines for beneficiary inclusion in the Medicaid FFS and Medicaid MCO Pharmacy Lock-In Programs.
D.C. Mun. Regs. tit. 29, r. 29-2714